The Journal of Practical Medicine >
Application value of adenosine injection in paclitaxel release coronary balloon catheter dilation
Received date: 2023-11-16
Online published: 2024-06-14
Objective To evaluate the value of adenosine injection in paclitaxel eluting PTCA balloon catheter. Methods A total of 200 patients undergoing drug-coated balloon angioplasty were randomly divided into control group receiving conventional treatment after the procedure， and observation group receiving adenosine injection for 3 hours continuously. All patients underwent coronary SYNTAX II scoring， and CK-MB， NT-proBNP， hs-CRP levels were recorded before and after PTCA for 6 hours， 12 hours， 18 hours， and 24 hours. A dedicated Israeli cardiac machine D-SPECT was used for rest + stress myocardial perfusion radionuclide imaging before and after the PTCA for 7 days. The total myocardial perfusion score under rest + stress myocardial perfusion in 17 segments was observed， as well as the adverse drug reactions after the PTCA. Results There were no significant differences in clinical characteristics， concomitant medication upon admission， coronary SYNTAX II score and PTCA treatment， mean target vessel stenosis， mean balloon diameter and length， CK-MB， NT-proBNP， hs-CRP before PTCA， and total myocardial perfusion score values under resting and stress myocardial perfusion distribution in 17 segments between the two groups（P > 0.05）. The CK-MB， NT-proBNP， and hs-CRP values in the experimental group were significantly lower than those in the control group at 6， 12， 18， and 24 hours after PTCA （P < 0.05）；The total myocardial perfusion score under resting and stress myocardial perfusion distribution in 17 segments was significantly lower in the experimental group than in the control group at 7 days after PTCA（P < 0.05）；There was no significant difference in adverse drug reactions between the two groups of patients after PTCA（P > 0.05）. Conclusions The application of adenosine injection in patients after drug-coated balloon therapy significantly reduced the CK-MB， NT-proBNP， and hs-CRP values 24 hours after PTCA， as well as the total myocardial perfusion score under resting and stress myocardial perfusion distribution in 17 segments 7 days after PTCA， without increasing significant adverse reactions.
Key words： adenosine injection; drug coated balloon; PTCA; D-SPECT
Liu LI , Qinghou ZHENG , Yu WANG , Le WANG , Qincong CHEN , Shuo WANG . Application value of adenosine injection in paclitaxel release coronary balloon catheter dilation[J]. The Journal of Practical Medicine, 2024 , 40(12) : 1712 -1718 . DOI: 10.3969/j.issn.1006-5725.2024.12.017
| 1 | 张闻多， 于雪， 季福绥， 等. 《药物涂层球囊治疗冠心病最新专家共识》解读［J］. 中国临床医生杂志， 2020， 48（8） ： 901-902. doi:10.3969/j.issn.2095-8552.2020.08.008 |
| 2 | LOH J P， BARBASH I M， WAKSMAN R. The current status of drug coated balloons in percutaneous coronary and peripheral interventions［J］. Euro Intervention， 2013， 9（8）： 979-988. |
| 3 | HWANG C W， WU D， EDELMAN E R. Physiological transport forces govern drug distribution for stent-based delivery［J］. Circulation， 2001， 104（5）： 600-605. |
| 4 | CREMERS B， TONER J L， SCHWARTZ L B， et al. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter［J］. Clin Res Cardiol， 2012， 101（6）： 469-476. |
| 5 | KLEBER F X， MATHEY D G， RITTGER H， et al. How to use the drug- eluting balloon： recommendations by the German consensus group［J］. Euro Intervention， 7（ ）： K125-K128. |
| 6 | ITO H. No reflow phenomenon in acute myocardial infarction［J］.Nihon Rinsho， 2011， 69（）： 142-146. |
| 7 | NICCOLI G， RIGATTIERI S， DE VITA M R， et al. Openlabel， randomized， placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction：the REOPEN-AMI study（Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction）［J］. JACC Cardiovasc Interv， 2013， 6（6）： 580-589. |
| 8 | WAN T C， GE Z D， TAMPO A， et al. The A3 adenosine receptor ago-nist CP-532， 903 ［N6-（2，5-dichlorobenzyl）-3'-aminoadenosine-5'-N-methylcarboxamide］ protects against myocardial ischemia /reper- fusion injury via the sarcolemmal ATP-sensitive potassium channel ［J］. J Pharmacol Exp Ther， 2008， 324（1） ： 234-243. |
| 9 | 杨旭. 替罗非班及三磷酸腺苷治疗冠脉介入术中无复流的疗效对比［J］. 临床研究， 2021， 29（8）：83-85. |
| 10 | 葛均波， 徐永健. 内科学［M］. 8版. 北京：人民卫生出版社， 2014：227. |
| 11 | NICCOLI G， RIGATTIERI S， DE VITA M R， et al. Openlabel， randomized， placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction：the REOPEN-AMI study（Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction）［J］. JACC Cardiovasc Interv， 2013， 6（6）：580-589. |
| 12 | 《药物涂层球囊临床应用中国专家共识》专家组. 药物涂层球囊临床应用中国专家共识［J］. 中国介入心脏病学杂志， 2016， 24（2）：61-67. |
| 13 | 张涵，秦珊珊，樊鑫，等. D-SPECT在冠心病患者早期诊断和心功能评估中的价值［J］. 同济大学学报（医学版）， 2019，40（2）：152-156. |
| 14 | 黄震华. 新型腺苷A_（2A）受体激动药瑞加诺生在心肌灌注显像中的应用［J］. 中国新药与临床杂志， 2010，29（10）：793-796. |
| 15 | 张倩，张海鹰，霍艳雷，等. D-SPECT评价体外心脏震波治疗对PCI术后患者血流灌注及心功能的影响［J］. 同济大学学报（医学版）， 2022，43（1）：90-94. |
| 16 | GIBBONS R J， ABRAMS J， CHATTERJEE K. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article： a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines （Committee on the Management of Patients With Chronic Stable Angina）［J］. Circulation， 2003， 107（1）：149. |
| 17 | 罗巍， 丁家崇， 周海依. 急性冠脉综合征行急诊PCI术后hs-CRP和NT-proBNP的临床意义及其预测价值［J］. 心脏杂志，2012，24（1）：63-66. |
| 18 | 赵水平， 胡大一. 心血管病诊疗指南解读［M］. 北京： 人民卫生出版社， 2008： 580-581. |
| 19 | RIFAI N， RIDKER P M. High sensitivity C-reactive protein： a novel and promising marker of coronary heart disease［J］. Clin Chem， 2001， 47（3） ： 403-411. |
| 20 | 罗贵全， 黄刚， 唐川苏， 等. 急性心肌梗死患者高敏C反应蛋白浓度变化及阿托伐他汀的干预效应［J］. 中西医结合心脑血管病杂志， 2013， 11（9）： 1074-1075. doi:10.3969/j.issn.1672-1349.2013.09.026 |
| 21 | 张春英， 侯旭敏， 仇兴标， 等. 冠心病 PCI 术后发生氯吡格雷抵抗的影响因素［J］. 上海交通大学学报（医学版）， 2012， 32 （ 6） ： 792-795. |
| 22 | 张叶萍， 刘波， 刘国宏， 等. 超敏C-反应蛋白与冠心病患者PCI术后支架内血栓形成的相关性［J］. 中国老年学杂志， 2017， 37（23）： 5815-5817. doi:10.3969/j.issn.1005-9202.2017.23.029 |
| 23 | 中华医学会心血管病学分会基础研究学组， 中华医学会心血管病学分会介入心脏病学组， 中华医学会心血管病学分会女性心脏健康学组， 中华医学会心血管病学分会动脉粥样硬化和冠心病学组.冠状动脉微血管疾病诊断和治疗的中国专家共识［J］. 中国循环杂志， 2017，32（5）：421-430. doi:10.3969/j.issn.1000-3614.2017.05.003 |
| 24 | 范强. 注射用尼克地尔联合替罗非班治疗PCI术后冠脉慢复流疗效观察［J］. 临床医药文献杂志， 2018，5（96）：151-156. |
| 25 | KATO R， FOEX P. Myocardial protection by anesthetic agents against ischemia-reperfusion injury：an update for anethesiologists ［J］. Can J Anaesth， 2002， 4（98）： 777-791. |
| 26 | 潘薇. 腺苷药物应用治疗心血管疾病研究进展［J］. 人人健康杂志， 2020，12：290. |
| 27 | STEENSRUD T， LI J， DAI X， et al. Pretreatment with the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote limb ischemia or intra-arterial adenosine ［J］.Am J Physiol Heart Circ Physiol， 2010， 299（5） ：1598-1603. |
| 28 | 杨洋， 陈东风. A2B腺苷受体相关疾病的研究进展［J］. 解放军医学杂志， 2019， 44（12）： 1061-1066. doi:10.11855/j.issn.0577-7402.2019.12.13 |
| 29 | XI L， DAS A， ZHAO Z Q， et al. Loss of myocardial ischemic postcon- ditioning in adenosine A1 and bradykinin B2 receptors gene knock- out mice ［J］. Circulation， 2008， 118（14 ）： S32-37. |
| 30 | KE J J， YU F X， RAO Y， et al. Adenosine postconditioning protects a- gainst myocardial ischemia-reperfusion injury though modulate pro- duction of TNF-α and prevents activation of transcription factor NF- kappaB ［J］. Mol Biol Rep， 2011， 38（1）： 531-538. |
| 31 | SCARPONE M， CENKO E， MANFRINI O. Coronary No-Reflow Phenomenon in Clinical Practice［J］. Curr Pharm Des， 2018， 24 （25）： 2927- 2933. |
| 32 | ASSALI A R， SDRINGOLA S， GHANI M， et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of no reflow phenomenon［J］. Catheter Cardiovasc Interv， 2000， 51（1）： 27-31. |
/
| 〈 |
|
〉 |